A Phase Ib, Dose Finding Study Evaluating AZD1775 in Monotherapy, in Combination With Carboplatin and Paclitaxel, and in Combination With Only Carboplatin in Adult Asian Patients With Advanced Solid Tumours

Trial Profile

A Phase Ib, Dose Finding Study Evaluating AZD1775 in Monotherapy, in Combination With Carboplatin and Paclitaxel, and in Combination With Only Carboplatin in Adult Asian Patients With Advanced Solid Tumours

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 29 May 2017

At a glance

  • Drugs AZD-1775 (Primary) ; Carboplatin; Paclitaxel
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 24 May 2017 Planned End Date changed from 1 Jun 2018 to 27 Jun 2018.
    • 24 May 2017 Status changed from recruiting to active, no longer recruiting.
    • 21 Feb 2017 Status changed from active, no longer recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top